Drug Development – Talk Bio

Odyssey Therapeutics Appoints Dennis Dean as EVP, Head of Non-Clinical Development

4 days ago talkbio0Tagged Autoimmune Diseases, Biological Factors, Dennis Dean, Drug Development, executive vice president, Head of Non-Clinical Development, Odyssey Therapeutics, preclinical research

Odyssey Therapeutics; Dennis Dean; Executive Vice President; Head of Non-Clinical Development; preclinical research; autoimmune diseases; drug development; biopharmaceutical

Voyager Therapeutics Partners with Transition Bio for Small Molecule Neurodegenerative Drug Discovery; CRISPR Therapeutics Ends Work on CAR-T Therapy

5 days ago talkbio0Tagged Amyotrophic Lateral Sclerosis, CAR-T therapy, Clustered Regularly Interspaced Short Palindromic Repeats, Drug Development, Neurodegenerative Disorders, Partnership, Pick Disease of the Brain, small molecule drug discovery, TARDBP gene, Transition Bio, Voyager Therapeutics

Voyager Therapeutics; Transition Bio; ALS; frontotemporal dementia; TDP-43; small molecule drug discovery; neurodegenerative diseases; CRISPR Therapeutics; CAR-T therapy; partnership; drug development

Dr. Andreas Wallnöfer Named to Optigo Biotherapeutics Board of Directors

2 weeks ago talkbio0Tagged Andreas Wallnöfer, Biotechnology, board of directors, Dosage Forms, Drug Development, Hyaluronic Acid anchoring platform, IND-enabling studies, Ophthalmology specialty, Optigo Biotherapeutics, R&D, Retinal Diseases

Andreas Wallnöfer; Optigo Biotherapeutics; Board of Directors; ophthalmology; biotechnology; retinal diseases; IND-enabling studies; Hyaluronic Acid anchoring platform; pharmaceutical R&D; drug development

Life Biosciences Appoints Industry Veteran David Guyer, M.D. to Board of Directors

2 weeks ago talkbio0Tagged Aging, Biotechnology, board of directors, cellular rejuvenation, David Guyer, Drug Development, epigenetic reprogramming, ER-100, Life Biosciences

Life Biosciences; David Guyer; Board of Directors; biotechnology; cellular rejuvenation; epigenetic reprogramming; ER-100; aging; drug development

Takeda Makes Pipeline Cuts and Faces Softer Q2 Sales Due to Generic Competition

2 weeks ago talkbio0Tagged Drug Development, Generic competition, impairment charges, Late stage, Operating, pipeline, Q2 sales, restructuring, Takeda, Vyvanse

Takeda; pipeline cuts; generic competition; Q2 sales; Vyvanse; restructuring; operating profit; impairment charges; drug development; late-stage pipeline

Creative Biolabs Sets the Bar Higher in Human Antibody Discovery with Cutting-Edge Platforms

3 weeks ago talkbio0Tagged AI-driven, antibody libraries, Creative Biolabs, Discover, Drug Development, Generative AI, human antibody, platforms

Creative Biolabs; human antibody discovery; AI-driven platforms; generative AI; antibody libraries; drug development

Alector’s GSK-partnered dementia drug latozinemab fails in late-stage trial

4 weeks ago talkbio0Tagged Alector, Clinical trial failure, Drug Development, Latozinemab, Phase 3 trial, Pick Disease of the Brain, Presenile dementia, Progranulins, SmithKline Beecham

Alector; GSK; latozinemab; dementia; frontotemporal dementia; Phase 3 trial; clinical trial failure; progranulin; drug development

Former FDA Deputy Dr. Namandjé N. Bumpus to Lead Charles River’s New Scientific Advisory Board

1 month ago talkbio0Tagged alternative testing, Animal Welfare, biopharmaceutical innovation, Charles River Laboratories, Drug Development, Namandjé Bumpus, NAMs, New Approach Methodologies, Scientific Advisory Board, United States Food and Drug Administration

Namandjé Bumpus; Charles River Laboratories; Scientific Advisory Board; FDA; New Approach Methodologies; NAMs; alternative testing; drug development; animal welfare; biopharmaceutical innovation

Novartis Again Partners with Argo Biopharma in $5.2B+ RNAi Cardiovascular Deal

2 months ago talkbio0Tagged ANGPTL3, Biopharma, biotech collaboration, cardiovascular pipeline, Drug Development, Dyslipidemias, milestone payments, Novartis, RNA Interference, RNA, Small Interfering

Novartis; Argo Biopharma; RNA interference (RNAi); siRNA; cardiovascular pipeline; ANGPTL3; dyslipidemia; biotech collaboration; drug development; milestone payments

Zymeworks Halts Development of ZW171 T-cell Engager After Phase 1 Trial Assesses Benefit-Risk Profile

2 months ago talkbio0Tagged benefit-risk profile, Clinical Trials, Dose-Limiting, Drug Development, Malignant Neoplasms, mesothelin, T-Cell engager, Toxicity aspects, ZW171, Zymeworks

Zymeworks; ZW171; T-cell engager; mesothelin; cancer; clinical trial; drug development; benefit-risk profile; dose-limiting toxicity